Chiesi Farmaceutici SpA (Chiesi) develops and commercializes innovative therapeutic products. The company offers drug delivery equipment with marketing and sales offices across Europe. The company’s development activities focus on major therapeutic areas including respiratory, neonatology, special care and rare diseases. Chiesi’s respiratory products are used for treating chronic obstructive pulmonary disease (COPD) and asthma. Its major respiratory products include Trimbow spray; Foster spray and Foster NEXThaler fixed combinations for inhalation of formoterol fumarate (bronchodilator) and beclomethasone dipropionate (anti-inflammatory) for the treatment of asthma; Atimos Modulite-based spray formulation (pMDI) of formoterol fumarate indicated for the prevention and treatment of bronchospasm in patients with COPD; and Clenil range of beclomethasone-containing products indicated for a range of inflammation-driven respiratory diseases including allergic rhinitis, asthma and branch stenosis. The company also offers Brexin (Piroxicam ß-cyclodextrin), a non-steroidal anti-inflammatory drug for the symptomatic treatment of inflammatory conditions in patients suffering from ankylosing spondylitis, rheumatoid arthritis and osteoarthritis. The company’s cardiovascular products help treat multi-factored illnesses such as myocardial infarction and ischemic ictus. Iperten (manidipine) is a long-lasting calcium-channel blocker, indicated for the treatment of mild-to-moderate hypertension. Vivace is a fixed combination of two antihypertensive agents, delapril (an ACE-inhibitor) and manidipine (a calcium-channel blocker) indicated for the treatment of essential hypertension in patients not adequately controlled by delapril monotherapy. Chiesi’s neonatology drugs are used for the treatment of apnoea of prematurity; and respiratory distress syndrome (RDS).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Chiesi’s R&D efforts focuses on developing treatments for rare diseases in the areas of respiratory, neonatology and specialist medicine. The company is handling various projects targeted at the investigation of the clinical profile of its advanced products. Its R&D centre includes Parma (Italy), Paris (France), Cary (the US), Lidingo (Sweden), Chippenham (the UK), Shanghai (China) and Toronto (Canada). The company focuses on collaborations and partnerships with other pharmaceutical companies for the development of its pipeline products. As of December 31, 2022, the company held more than 42 patents.